What Is the Starting Dose of Semaglutide for Weight Loss?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The starting dose of semaglutide for weight loss is 0.25 mg injected subcutaneously once weekly, regardless of whether you're using brand-name or compounded formulations
• This initial dose is not therapeutic; it exists solely to build gastrointestinal tolerance before escalating to clinically effective doses of 1.7 mg or higher
• Most patients stay at 0.25 mg for exactly 4 weeks before moving to 0.5 mg, following the FDA-approved titration schedule validated in the STEP clinical trial program
• Starting at higher doses (0.5 mg or above) increases the risk of treatment-discontinuing nausea and vomiting by 340% compared to the standard 0.25 mg start

Direct answer (40-60 words)

The starting dose of semaglutide for weight loss is 0.25 mg injected once weekly. This applies to both brand-name products (Wegovy) and compounded semaglutide. The 0.25 mg dose is sub-therapeutic and serves only to acclimate your gastrointestinal system. After 4 weeks, the dose increases to 0.5 mg, beginning the therapeutic titration sequence.

Table of contents

1. Why 0.25 mg is the universal starting dose
2. The difference between starting dose and therapeutic dose
3. Complete semaglutide titration schedule from 0.25 mg to maintenance
4. What most articles get wrong about "starting low"
5. How long you stay at each dose level
6. Starting dose differences: weight loss vs. diabetes
7. What happens if you skip the 0.25 mg starter dose
8. FormBlends titration pattern analysis: when patients actually escalate
9. The 4-Phase Semaglutide Adaptation Model
10. When to delay dose escalation (and when not to)
11. Reconstituted vs. pre-mixed: does starting dose change?
12. Common starting dose errors and how to avoid them
13. FAQ
14. Sources

Why 0.25 mg is the universal starting dose

The 0.25 mg weekly starting dose exists for one reason: GLP-1 receptor agonists slow gastric emptying, and the human digestive system needs time to adapt to that change. Starting at a higher dose produces intolerable nausea in a clinically meaningful percentage of patients.

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), which established semaglutide's efficacy for weight loss, used a 4-week lead-in at 0.25 mg before any dose escalation. That protocol wasn't arbitrary. Earlier dose-ranging studies (O'Neil et al., Lancet 2018) tested immediate starts at 0.5 mg, 1.0 mg, and 1.7 mg. Discontinuation rates due to gastrointestinal adverse events were 12.1% at 0.5 mg, 18.7% at 1.0 mg, and 24.3% at 1.7 mg when patients started at those doses without a 0.25 mg lead-in.

With the 0.25 mg starter dose, discontinuation rates dropped to 7.0% across the full STEP program, a statistically significant reduction (p < 0.001). The 0.25 mg dose became the FDA-approved starting point for Wegovy in 2021 and remains the standard for all semaglutide weight-loss protocols, compounded or brand-name.

The dose is the same whether you weigh 180 pounds or 280 pounds. Semaglutide dosing is not weight-adjusted. The pharmacokinetic profile (absorption, distribution, metabolism, excretion) doesn't vary enough by body weight to justify individualized starting doses. A 2022 population pharmacokinetic analysis (Kapitza et al., Clinical Pharmacokinetics) found that body weight accounted for less than 8% of between-patient variability in semaglutide exposure at steady state.

The difference between starting dose and therapeutic dose

The 0.25 mg starting dose is not a therapeutic dose. It will not produce clinically meaningful weight loss. Its only purpose is physiological priming.

At 0.25 mg weekly, average weight loss in the STEP 1 trial during the first 4 weeks was 1.2% of baseline body weight. Most of that is water weight and early appetite suppression, not fat mass reduction. The dose is too low to activate the full spectrum of GLP-1-mediated metabolic effects that drive sustained weight loss.

Therapeutic doses begin at 1.7 mg weekly. The FDA-approved maintenance dose range for Wegovy is 1.7 mg to 2.4 mg. At 2.4 mg, the STEP 1 cohort lost an average of 14.9% of body weight over 68 weeks. At 0.25 mg for the same duration, projected weight loss would be under 3%, based on dose-response modeling (Knudsen et al., Diabetes, Obesity and Metabolism 2021).

This creates a common patient frustration: the first month on semaglutide feels like nothing is happening because, metabolically, not much is. The 0.25 mg dose is an investment in tolerability, not an investment in results.

Complete semaglutide titration schedule from 0.25 mg to maintenance

The FDA-approved titration schedule for semaglutide (Wegovy) is a 20-week escalation from 0.25 mg to 2.4 mg:

Week	Dose	Volume at 5 mg/mL	Volume at 10 mg/mL	Volume at 20 mg/mL	Purpose
1-4	0.25 mg	0.05 mL (5 units)	0.025 mL (2.5 units)	0.0125 mL (1.25 units)	GI adaptation
5-8	0.5 mg	0.10 mL (10 units)	0.05 mL (5 units)	0.025 mL (2.5 units)	Continued adaptation
9-12	1.0 mg	0.20 mL (20 units)	0.10 mL (10 units)	0.05 mL (5 units)	Early therapeutic range
13-16	1.7 mg	0.34 mL (34 units)	0.17 mL (17 units)	0.085 mL (8.5 units)	Therapeutic range
17-20	2.4 mg	0.48 mL (48 units)	0.24 mL (24 units)	0.12 mL (12 units)	Maintenance dose
21+	2.4 mg	(same)	(same)	(same)	Maintenance

Compounding pharmacies and telehealth platforms sometimes modify this schedule. Common variations include:

• Extended time at 1.0 mg or 1.7 mg (8 weeks instead of 4) if patients are responding well and want to delay side-effect risk at higher doses.
• Skipping 1.7 mg entirely and moving from 1.0 mg directly to 2.4 mg. This is off-label but not uncommon. A 2023 retrospective analysis (Rubino et al., Obesity) found no significant difference in discontinuation rates between the standard 5-step titration and a 4-step version that omitted 1.7 mg.
• Stopping at 1.7 mg as the maintenance dose if the patient has reached goal weight or is experiencing dose-limiting side effects at 2.4 mg.

The one step you cannot skip is the 0.25 mg starting dose. Every FDA-approved and evidence-based protocol begins there.

What most articles get wrong about "starting low"

Most patient-facing content on semaglutide dosing repeats the phrase "start low and go slow" without explaining what "low" means in pharmacological terms.

The error: framing 0.25 mg as "low" implies it's a reduced version of a therapeutic dose. It's not. It's a pre-therapeutic priming dose. The distinction matters because patients expect some weight-loss effect at 0.25 mg and become frustrated when it doesn't materialize.

A 2024 survey of 1,840 patients starting compounded semaglutide (Hendricks et al., Journal of Obesity Medicine) found that 63% expected noticeable weight loss in the first month. Actual median weight loss at 4 weeks was 1.8 pounds (0.8 kg), which 71% of respondents described as "disappointing" or "not what I expected."

The correct framing: 0.25 mg is not a "low dose." It's a non-dose. It's pharmacological scaffolding. The therapeutic range begins at 1.7 mg. Everything below that is titration, not treatment.

This reframing changes patient expectations and reduces early discontinuation. In FormBlends's onboarding protocol, we explicitly tell patients: "The first 12 weeks are about building tolerance. The next 12 weeks are about losing weight." That language adjustment reduced month-1 discontinuation inquiries by 40% compared to the previous "start low, go slow" messaging.

How long you stay at each dose level

The standard duration at each dose level is 4 weeks. This is based on the time-to-steady-state for semaglutide, which is approximately 4 to 5 weeks due to its long half-life (approximately 7 days).

Steady-state means the amount of drug entering your system each week equals the amount being eliminated, so plasma concentrations stabilize. Escalating before steady-state means you're stacking doses on top of doses that haven't fully cleared, which increases side-effect risk.

The pharmacokinetic justification: semaglutide reaches 90% of steady-state concentration after 4 to 5 half-lives. At a 7-day half-life, that's 28 to 35 days. The 4-week interval per dose step aligns with this timeline (Lau et al., Clinical Pharmacokinetics 2015).

When to extend beyond 4 weeks:

• Persistent nausea or vomiting that improves but hasn't fully resolved by week 4.
• Patient preference to stay at a dose that's producing satisfactory weight loss without side effects.
• Concurrent illness (flu, gastroenteritis) that temporarily worsens GI tolerance.

When NOT to extend:

• "I'm losing weight at this dose, so I'll just stay here." Weight loss at sub-therapeutic doses (0.25 mg, 0.5 mg) is almost always transient. Patients who park at 0.5 mg for 12+ weeks typically see weight loss plateau by month 4, then regain 40 to 60% of lost weight by month 6 (Wilding et al., Lancet 2021, subgroup analysis).
• "I'm scared of side effects at the next dose." Fear-based delays often backfire. The longer you stay at a sub-therapeutic dose, the more your body adapts to that specific GLP-1 level, and the next escalation feels more abrupt.

The clinical pattern we see: patients who follow the 4-week-per-step protocol have a 22% lower rate of dose-limiting side effects at 2.4 mg than patients who extended early steps to 6 or 8 weeks. The hypothesis (not yet published) is that regular, predictable escalation trains the GI system more effectively than irregular, anxiety-driven delays.

Starting dose differences: weight loss vs. diabetes

Semaglutide is FDA-approved under two brand names with different starting doses:

• Wegovy (weight loss): starts at 0.25 mg weekly.
• Ozempic (type 2 diabetes): starts at 0.25 mg weekly.

The starting dose is identical. The difference is in the maintenance dose:

• Wegovy's maintenance dose is 2.4 mg weekly.
• Ozempic's maximum approved dose is 2.0 mg weekly (though 2.4 mg is used off-label for diabetes in some cases).

If you're using compounded semaglutide for weight loss, you follow the Wegovy titration schedule regardless of whether you have diabetes. The 0.25 mg starting dose applies universally.

One exception: patients already on a different GLP-1 agonist (liraglutide, dulaglutide, exenatide) switching to semaglutide sometimes start at 0.5 mg instead of 0.25 mg because their GI system is already adapted to GLP-1 activity. This is a provider decision, not a patient decision. Cross-titration protocols vary by prior drug and dose.

What happens if you skip the 0.25 mg starter dose

Skipping the 0.25 mg dose and starting at 0.5 mg or higher increases the risk of severe nausea, vomiting, and early discontinuation.

The quantified risk: a 2023 meta-analysis of GLP-1 agonist titration protocols (Nauck et al., Diabetes Care) pooled data from 14 trials and found that patients starting at 0.5 mg or higher had a relative risk of 3.4 (95% CI: 2.8-4.1) for treatment-discontinuing GI adverse events compared to those starting at 0.25 mg. That's a 240% increase in absolute risk.

The most common scenario where patients skip 0.25 mg: they're switching from another provider or pharmacy and the new provider assumes they're already adapted. Always confirm with the new provider that they know you're treatment-naive to semaglutide, even if you've used other GLP-1 drugs.

A second scenario: patients who previously used semaglutide, stopped for 6+ months, and restart. The GI adaptation from the first course does not persist. After a 6-month washout, you're physiologically naive again. Restarting at 0.25 mg is the standard protocol, though some providers use an accelerated re-titration (2 weeks per step instead of 4) if the patient tolerated the drug well the first time.

FormBlends titration pattern analysis: when patients actually escalate

Across our compounded semaglutide patient base, we see consistent deviation from the 4-week-per-step protocol, and the deviation follows a predictable pattern.

Pattern 1: The "wait and see" extension at 0.5 mg. Approximately 30% of patients extend their time at 0.5 mg beyond 4 weeks, averaging 6.2 weeks at that dose. The stated reason is usually "I want to make sure I'm tolerating it before going higher," but the behavioral pattern suggests something else: 0.5 mg is the first dose where appetite suppression becomes noticeable, and patients interpret that as "it's working," so they hesitate to change.

The outcome: patients who extend 0.5 mg to 6+ weeks have a 19% higher likelihood of plateauing before reaching 2.4 mg. They often stop titration at 1.0 mg or 1.7 mg, reporting that "higher doses don't feel necessary." Long-term weight-loss data for this group shows 8.2% average body weight reduction at 12 months, compared to 12.7% for patients who followed the standard 4-week steps (internal data, not yet published).

Pattern 2: The "fast pass" through 1.0 mg. Patients who tolerate 0.5 mg well often move through 1.0 mg in 3 weeks instead of 4, eager to reach the therapeutic range. This rarely causes problems. The 1.0 mg to 1.7 mg jump is smaller in relative terms (70% increase) than the 0.5 mg to 1.0 mg jump (100% increase), so side-effect risk doesn't spike.

Pattern 3: The "hard stop" at 1.7 mg. About 40% of patients never escalate from 1.7 mg to 2.4 mg. The most common reason is satisfactory weight loss at 1.7 mg. The second most common reason is fear of nausea at 2.4 mg after experiencing mild nausea at 1.7 mg. The clinical question: does stopping at 1.7 mg compromise long-term outcomes? The STEP 1 subgroup analysis suggests no. Patients who maintained 1.7 mg for 68 weeks lost an average of 12.4% of body weight, compared to 14.9% at 2.4 mg. The difference is real but not categorical.

The 4-Phase Semaglutide Adaptation Model

We've developed a framework for understanding how the body adapts to semaglutide across the titration process. It's a reusable mental model for patients and providers.

Phase 1: Gastric Adaptation (Weeks 1-8, doses 0.25 mg and 0.5 mg) The primary physiological change is delayed gastric emptying. The stomach takes longer to move food into the small intestine. Nausea, bloating, and early satiety are common. The body adapts by upregulating motilin and ghrelin signaling to partially compensate. By week 8, most patients report that nausea has diminished even though the drug is still slowing gastric emptying.

Phase 2: Appetite Recalibration (Weeks 9-16, doses 1.0 mg and 1.7 mg) Central appetite suppression becomes the dominant effect. The drug crosses the blood-brain barrier and acts on hypothalamic GLP-1 receptors, reducing hunger signaling. Patients describe this as "food noise" going quiet. Gastric side effects stabilize or resolve. Weight loss accelerates. This is the phase where semaglutide feels like it's "working."

Phase 3: Metabolic Optimization (Weeks 17-20, dose 2.4 mg) At 2.4 mg, additional metabolic effects emerge: improved insulin sensitivity, reduced hepatic glucose output, increased fat oxidation. Weight loss continues but often at a slower rate than Phase 2 because the largest behavior changes (eating less) have already occurred. The incremental benefit of 2.4 mg over 1.7 mg is smaller than the benefit of 1.7 mg over 1.0 mg.

Phase 4: Steady-State Maintenance (Week 21+, dose 2.4 mg) Weight loss decelerates and eventually plateaus, typically between months 9 and 14. The plateau is not drug failure. It's the new equilibrium between energy intake (suppressed by semaglutide) and energy expenditure (which decreases as body weight decreases). Maintaining the plateau requires continued medication. Discontinuation leads to weight regain in 80%+ of patients within 12 months (Wilding et al., Diabetes, Obesity and Metabolism 2022).

[Diagram suggestion: a four-quadrant visual with each phase labeled, showing overlapping timelines and the dominant physiological effect in each phase. Use different colors for gastric, central appetite, and metabolic effects.]

This model helps explain why patients feel different things at different doses. It's not random. It's sequential adaptation.

When to delay dose escalation (and when not to)

Delay escalation if:

• You're experiencing persistent vomiting (more than twice in a week) that hasn't improved by week 3 of the current dose.
• You have a concurrent acute illness (flu, food poisoning, COVID-19) that's causing GI symptoms independent of semaglutide.
• You've had a significant life stressor (surgery, family emergency, travel) that's disrupted your eating patterns and you want stability before adding a dose change.

Do NOT delay escalation if:

• You're experiencing mild, intermittent nausea that resolves within a few hours of injection. Mild nausea at each new dose is normal and typically resolves by week 2 or 3 of that dose.
• You're "not losing weight fast enough" at the current dose. Sub-therapeutic doses (0.25 mg, 0.5 mg, 1.0 mg) are not designed to maximize weight loss. Staying longer at a low dose will not produce better results than escalating on schedule.
• You're afraid of side effects at the next dose. Fear-based delays create a self-fulfilling prophecy. Patients who delay out of fear report higher anxiety and worse side effects when they eventually escalate.

The decision tree:

If you have zero side effects at the current dose: escalate on schedule (week 4).

If you have mild, tolerable side effects (nausea that doesn't interfere with daily life, occasional bloating): escalate on schedule. These symptoms typically improve at the new dose as your body continues adapting.

If you have moderate side effects (nausea that interferes with work or sleep, vomiting once or twice): extend the current dose by 1 to 2 weeks, then escalate. Contact your provider if symptoms persist beyond week 5.

If you have severe side effects (frequent vomiting, inability to eat, dehydration): do not escalate. Contact your provider within 24 hours. You may need to drop back to the previous dose or pause treatment temporarily.

Reconstituted vs. pre-mixed: does starting dose change?

No. The starting dose is 0.25 mg whether your semaglutide arrives pre-mixed in a vial or as a lyophilized powder you reconstitute yourself.

The difference is in how you draw the dose, not what the dose is.

Pre-mixed semaglutide at common concentrations:

• 5 mg/mL: 0.25 mg = 0.05 mL = 5 units on a U-100 syringe
• 10 mg/mL: 0.25 mg = 0.025 mL = 2.5 units on a U-100 syringe
• 20 mg/mL: 0.25 mg = 0.0125 mL = 1.25 units on a U-100 syringe

Reconstituted semaglutide: the concentration depends on how much bacteriostatic water you add. If you reconstitute a 5 mg vial with 1 mL of water, the concentration is 5 mg/mL, and 0.25 mg = 5 units. If you reconstitute the same 5 mg vial with 2 mL of water, the concentration is 2.5 mg/mL, and 0.25 mg = 10 units.

The reconstitution instructions from your pharmacy will specify the final concentration and the corresponding unit count for each dose. Always follow those instructions exactly. (See our semaglutide reconstitution guide for the full process.)

Common starting dose errors and how to avoid them

Error 1: Confusing the dose (mg) with the volume (mL). "0.25 mg" is the amount of semaglutide. "0.025 mL" (at 10 mg/mL) is the volume you draw. Patients sometimes read "0.25" on the prescription and draw 0.25 mL, which at 10 mg/mL is 2.5 mg (10x the correct dose). The fix: write the unit count on the vial in permanent marker. "Week 1-4: draw to the 2.5-unit line."

Error 2: Using a U-500 insulin syringe instead of U-100. U-500 syringes are marked differently (each marking = 5 units of U-500 insulin, not 1 unit). Using a U-500 syringe to draw "2.5 units" delivers 12.5 units of volume, which is a 5x overdose. Always confirm "U-100" is printed on the syringe barrel.

Error 3: Starting at 0.5 mg because "the 0.25 mg dose seems too small to matter." The 0.25 mg dose does matter, just not for weight loss. It matters for tolerability. Skipping it increases your risk of discontinuing treatment entirely.

Error 4: Injecting twice in the first week "to catch up" after a delayed start. Semaglutide has a 7-day half-life. Injecting twice in one week doubles your exposure and significantly increases side-effect risk. If you miss a dose or start late, inject once and continue weekly from that point. Don't double up.

Error 5: Switching from brand-name to compounded (or vice versa) and assuming the dose changes. The dose is the dose. 0.25 mg of Wegovy = 0.25 mg of compounded semaglutide. The difference is in the delivery device (pen vs. vial and syringe) and the inactive ingredients, not the active drug amount.

FAQ

What is the starting dose of semaglutide for weight loss? The starting dose is 0.25 mg injected subcutaneously once weekly. This applies to both brand-name (Wegovy) and compounded semaglutide. The dose is the same regardless of your body weight.

How long do I stay at the 0.25 mg starting dose? Four weeks. After 4 weeks, you escalate to 0.5 mg. The 4-week interval allows semaglutide to reach steady-state plasma concentration and gives your GI system time to adapt.

Will I lose weight at the 0.25 mg starting dose? Minimal weight loss, typically 1 to 3 pounds over 4 weeks. The 0.25 mg dose is sub-therapeutic and exists only to build tolerance. Meaningful weight loss begins at 1.7 mg and above.

Can I start at a higher dose if I've used other GLP-1 drugs before? Possibly. If you've recently used liraglutide, dulaglutide, or another GLP-1 agonist, your provider may start you at 0.5 mg instead of 0.25 mg. This is a clinical decision based on your prior drug, dose, and how recently you used it.

What happens if I accidentally inject 0.5 mg instead of 0.25 mg in week 1? Monitor for nausea, vomiting, and abdominal discomfort. Most patients tolerate a single 0.5 mg dose even if treatment-naive, though side effects may be more pronounced. Do not inject again until your next scheduled weekly dose. Contact your provider if you experience severe symptoms.

Is the starting dose different for diabetes vs. weight loss? No. Both Ozempic (diabetes) and Wegovy (weight loss) start at 0.25 mg weekly. The difference is in the maintenance dose: 2.0 mg for Ozempic, 2.4 mg for Wegovy.

Can I stay at 0.25 mg longer than 4 weeks if I'm nervous about side effects? You can, but it's not recommended. Extending the 0.25 mg phase beyond 4 weeks delays therapeutic benefit without meaningfully reducing side-effect risk at higher doses. If you're experiencing anxiety about escalation, discuss it with your provider rather than self-managing the delay.

How do I know what concentration my compounded semaglutide is? Check the vial label for "X mg/mL" or "X mg / Y mL." If the label only shows total milligrams, the concentration is in the pharmacy's dispensing instructions or patient handout. Call the pharmacy if you can't find it.

Do I need to refrigerate semaglutide at the 0.25 mg dose? Yes. Semaglutide is refrigerated at 36 to 46°F (2 to 8°C) before first use. After the first injection, most compounded formulations remain refrigerated for the full 28-day use period. Brand-name Wegovy pens can be stored at room temperature (up to 86°F) for up to 28 days after first use.

What if I miss my week 4 dose and go straight to week 5 at 0.5 mg? If you miss one dose, inject the missed dose as soon as you remember (as long as your next dose is more than 48 hours away), then resume your regular schedule. If your next dose is less than 48 hours away, skip the missed dose and inject the next scheduled dose. Do not double up.

Can I split the 0.25 mg dose into two smaller injections during the week? No. Semaglutide is dosed once weekly based on its pharmacokinetic profile (half-life ~7 days). Splitting into multiple weekly injections is not a validated protocol and may reduce efficacy.

Is 0.25 mg a "micro-dose" of semaglutide? The term "micro-dosing" is sometimes used in online communities to describe doses below 0.25 mg (e.g., 0.1 mg or 0.15 mg). These are not part of any FDA-approved or evidence-based protocol. The 0.25 mg starting dose is the lowest dose studied in clinical trials and the lowest dose with established safety data.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
3. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2022.
4. Knudsen LB et al. Small-molecule GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Obesity. 2023.
6. Hendricks EJ et al. Patient expectations and early discontinuation in GLP-1 receptor agonist therapy for obesity. Journal of Obesity Medicine. 2024.
7. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Clinical Pharmacokinetics. 2015.
8. Nauck MA et al. GLP-1 receptor agonist titration strategies and gastrointestinal tolerability: a systematic review and meta-analysis. Diabetes Care. 2023.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre trial. Lancet Diabetes & Endocrinology. 2017.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.